Durvalumab Administration: Dilution and Infusion Duration
Durvalumab 10 mg/kg should be diluted and administered as an intravenous infusion over 60 minutes, given every 2 weeks. 1
Preparation and Administration
Dilution Requirements
- Must be diluted before use - durvalumab cannot be administered undiluted 1
- The drug comes as a 50 mg/mL concentration (available as 120 mg/2.4 mL or 500 mg/10 mL single-dose vials) 1
- Dilute in appropriate IV solution per standard institutional protocols for monoclonal antibodies
Infusion Duration
- Standard infusion time: 60 minutes 1
- This 60-minute duration applies to all doses and is consistent across indications
Dosing Schedule Options
For patients weighing ≥30 kg, two FDA-approved dosing regimens exist:
- Weight-based dosing: 10 mg/kg IV every 2 weeks (original approval) 2, 3, 4
- Fixed dosing: 1500 mg IV every 4 weeks (approved November 2020) 5, 6
Both regimens are equivalent in efficacy and can be used for up to 12 months in the consolidation setting for stage III NSCLC 5, 2.
Important Safety Considerations
Infusion Reaction Management
While durvalumab has a relatively low incidence of infusion reactions (IRs), the ESMO guidelines for anti-PD-L1 agents like atezolizumab (a similar agent) recommend 7:
- No routine premedication required
- For Grade 1/2 reactions: Stop or slow the infusion rate, provide symptomatic treatment
- For Grade 3/4 reactions: Stop the infusion permanently and provide aggressive symptomatic treatment
Storage and Handling
- Store at 2°C to 8°C (36°F to 46°F) 1
- Do not freeze or shake
- Keep vial in original carton to protect from light
- Discard unused portion from single-dose vial
Clinical Context
The 60-minute infusion duration is standard across the durvalumab clinical trial program, including the pivotal PACIFIC trial for stage III NSCLC 2 and studies in other malignancies 3, 4. Real-world evidence confirms this infusion duration is well-tolerated in community practice settings 6.
The every 4-week fixed dosing regimen (1500 mg) offers equivalent outcomes with improved convenience compared to the every 2-week schedule, with similar treatment duration and completion rates in real-world practice 6.